CapsoVision (CV) EBT Margin (2024 - 2025)
CapsoVision (CV) reported EBT Margin of 188.11% for Q4 2025, down 5404.0% on a YoY basis from 3.55% in Q4 2024, and up 15.98% sequentially from 223.88% in Q3 2025.
CapsoVision (CV) EBT Margin (2024 - 2025) Analysis & Trends
CapsoVision (CV) has 2 years of EBT Margin data on file, last reported at 188.11% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin fell 5404.0% year-over-year to 188.11%; the trailing twelve-month figure through Dec 2025 stood at 172.57% (changed N/A YoY), and the FY2025 full-year result was 186.59%, down 1743.0% from the prior year.
- EBT Margin climbed to 188.11% in Q4 2025, from 223.88% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 134.07% in Q4 2024 to a low of 223.88% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | CapsoVision | 162.07 Mn | 151.95 Mn | 1.95 Mn | -188.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -188.11% |
| Sep 30, 2025 | -223.88% |
| Jun 30, 2025 | -139.52% |
| Dec 31, 2024 | -134.07% |
| Sep 30, 2024 | -195.35% |
| Jun 30, 2024 | -185.23% |